The Clinical and Economic Impact of Penicillin Allergy

项目摘要 候选人金伯利湾布卢门塔尔，医学博士，理学硕士是马萨诸塞州总医院的过敏症专家/免疫学家 (MGH)也是哈佛医学院的医学助理教授学习经济学后， 她毕业于哥伦比亚大学，在耶鲁大学获得医学博士学位。布卢门塔尔医生完成了内科学 在麻省总医院接受过敏/免疫学培训，在哈佛T.H.获得理学硕士学位。陈公学校 健康布卢门塔尔博士的目标是成为药物过敏流行病学和模拟研究的国际领导者。 指导，培训活动和环境。布卢门塔尔博士由罗谢尔P.瓦伦斯基指导， 医学博士，公共卫生硕士，直到她在2021年1月离开指导疾病控制和预防中心。博士 Walensky从2006年到2021年获得NIH资助;她成功地将>5名研究员转变为独立的R 01-R 02研究员。 资助的研究事业。布卢门塔尔博士目前的导师是卡洛斯卡马戈博士，一个国际公认的 过敏反应专家和NIH资助的流行病学家。布卢门塔尔博士掌握了新的技能， 大型数据库分析、资源利用分析、仿真建模和成本效益分析 分析.布卢门塔尔博士可利用的合作机会、知识环境和资源 是杰出的，并为她提供了一条明确的独立之路。 Research.据报道，超过10%的美国人口对青霉素（PCN）过敏，尽管自我报告的PCN 变态反应很少反映不能耐受多氯化萘和其它β-内酰胺抗生素。不必要地使用 β-内酰胺类替代抗生素导致更多的抗菌素耐药性和医疗相关感染。 β-内酰胺类抗生素是药物超敏反应的最常见原因，免疫介导的 药物不良反应的子集。PCN过敏评价可区分有和无 真正的PCN超敏反应K 01科学计划，青霉素过敏的临床和经济影响， 有三个具体目标与国家优先事项一致，包括遏制抗菌素耐药性： 1)评估报告的PCN过敏的临床和经济影响。 2)确定β-内酰胺类抗生素的使用频率、预测因素和医疗资源影响。 3)预测PCN过敏评价的临床结局、预算影响和成本效益。 完成本研究提案和培训计划将使布卢门塔尔博士能够进行独立研究 作为药物过敏专家的职业生涯，在临床流行病学和决策科学的方法技能。

PROJECT SUMMARY Candidate. Kimberly G. Blumenthal, MD, MSc is an allergist/immunologist at Massachusetts General Hospital (MGH) and an Assistant Professor of Medicine at Harvard Medical School. After studying economics at Columbia University, she received her MD from Yale University. Dr. Blumenthal completed Internal Medicine and Allergy/Immunology training at MGH, and a Masters of Science at the Harvard T.H. Chan School of Public Health. Dr. Blumenthal aims to be an international leader in drug allergy epidemiology and simulation research. Mentorship, Training Activities, and Environment. Dr. Blumenthal was mentored by Rochelle P. Walensky, MD, MPH until her departure in January 2021 to direct the Centers for Disease Control and Prevention. Dr. Walensky was NIH-funded from 2006-2021; she had successfully transitioned >5 fellows to independent R01- funded research careers. Dr. Blumenthal’s current mentor is Dr. Carlos Camargo, an internationally recognized expert in anaphylaxis and NIH-funded epidemiologist. Dr. Blumenthal has acquired new skills, including linkage and analysis of large databases, resource utilization analysis, and simulation modeling and cost-effectiveness analysis. The collaborative opportunities, intellectual environment, and resources available to Dr. Blumenthal are outstanding and provide her with a clear path to independence. Research. Penicillin (PCN) allergy is reported by over 10% of the U.S. population, though a self-reported PCN allergy infrequently reflects an inability to tolerate PCNs and other beta-lactam antibiotics. Unnecessary use of beta- lactam alternative antibiotics leads to more antimicrobial resistance and healthcare-associated infections. Beta-lactam antibiotics are the most common cause of drug hypersensitivity reactions, the immune-mediated subset of adverse drug reactions. PCN allergy evaluation can distinguish between patients with and without true PCN hypersensitivity. The K01 scientific program, The Clinical and Economic Impact of Penicillin Allergy, has three specific aims that align with national priorities including curbing antimicrobial resistance: 1) To assess the clinical and economic impact of reported PCN allergy. 2) To determine the frequency, predictors, and healthcare resource impact of beta-lactam antibiotics. 3) To project the clinical outcomes, budgetary impact, and cost-effectiveness of PCN allergy evaluation. Completion of this research proposal and training plan will position Dr. Blumenthal for an independent research career as a drug allergy expert with methods skills in clinical epidemiology and decision science.